Incyte Corporation INCY
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +21.53%
- 1 year
- +28.41%
- Open
- 119.02
- Prev close
- 120.39
- Mkt cap
- 24.47B
- Vol
- 1.75M
- Avg vol
- 1.61M
- EPS
- 1.95
- P/E
- 61.56
- Div yield
- 0.00%
More statistics
- Low
- 118.25
- High
- 121.52
- Forward P/E
- 13.86
- Beta
- 0.78
- Short ratio
- 5.61
- Inst. own
- 103.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 9, 2027
- 50-d avg
- 120.49
- 200-d avg
- 108.06
- 1y target
- 130.92
5D chart
Events in this range
- Oct 29, 2026Earnings: -3.6; estimate -3.93; surprise 8.4%
- Oct 30, 2026Rating: Oppenheimer · Perform → Outperform
- Oct 30, 2026Rating: Evercore ISI Group · In-Line → In-Line
- Oct 30, 2026Rating: Barclays · Overweight → Overweight
- Oct 30, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 30, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Nov 2, 2026Rating: Bernstein · Market Perform → Market Perform
Signals (148)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:55 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 9 hours ago |
| MACD: Sell Signal | Nov 2, 3:55 PM | 9 hours ago |
| MACD: Buy Signal | Nov 2, 3:50 PM | 9 hours ago |
| RSI: Overbought | Nov 2, 3:50 PM | 9 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 10 hours ago |
| RSI: Overbought | Nov 2, 3:35 PM | 10 hours ago |
| RSI: Overbought | Nov 2, 3:15 PM | 10 hours ago |
| RSI: Overbought | Nov 2, 2:45 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 1:45 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 1:40 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 1:30 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 1:15 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 1:05 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 12 hours ago |
| SMA: Bullish | Nov 2, 12:55 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:50 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 12:40 PM | 13 hours ago |
| SMA: Bearish | Nov 2, 12:25 PM | 13 hours ago |
Newest 20 of 148.
News
-
12 hours ago benzinga.com
Bernstein Maintains Market Perform on Incyte, Raises Price Target to $108
Bernstein analyst Jeffrey Walch maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $104 to $108.
-
3 days ago benzinga.com
Wells Fargo Maintains Equal-Weight on Incyte, Lowers Price Target to $127
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and lowers the price target from $128 to $127.
-
3 days ago benzinga.com
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $117
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $114 to $117.
-
3 days ago benzinga.com
Barclays Maintains Overweight on Incyte, Raises Price Target to $143
Barclays analyst Etzer Darout maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $139 to $143.
3 days ago benzinga.com
This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday
Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
-
3 days ago benzinga.com
Evercore ISI Group Maintains In-Line on Incyte, Raises Price Target to $127
Evercore ISI Group analyst Maneka Mirchandaney maintains Incyte (NASDAQ:INCY) with a In-Line and raises the price target from $125 to $127.
3 days ago 247wallst.com
Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
Pre-Market Stock Futures: Futures are trading lower this Friday, with the Nasdaq down almost 2.
3 days ago benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
3 days ago benzinga.com
Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.
-
3 days ago benzinga.com
Oppenheimer Upgrades Incyte to Outperform, Raises Price Target to $144
Oppenheimer analyst Jay Olson upgrades Incyte (NASDAQ:INCY) from Perform to Outperform and raises the price target from $120 to $144.
4 days ago seekingalpha.com
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. Q3 net…
4 days ago zacks.com
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised
Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.
4 days ago seekingalpha.com
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
Incyte Corporation (INCY) Q3 2026 Earnings Call Transcript
4 days ago marketbeat.com
What Incyte (INCY) Said on Its Q3 Earnings Call
Incyte NASDAQ: INCY reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in…
4 days ago zacks.com
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
4 days ago zacks.com
Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates
Incyte (INCY) came out with a quarterly loss of $3.6 per share versus the Zacks Consensus Estimate of a loss of $3.99. This compares to earnings of $2.26 per share a year ago.
4 days ago benzinga.com
Incyte Q3 2026 Earnings Call Transcript
Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
-
4 days ago benzinga.com
Incyte Raises FY2026 Sales Guidance from $5.130B-$5.260B to $5.210B-$5.300B vs $5.929B Est
Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $5.130 billion-$5.260 billion to $5.210 billion-$5.300 billion vs $5.929 billion estimate.
-
4 days ago benzinga.com
Incyte Q3 Adj. EPS $(3.60) Beats $(3.85) Estimate, Sales $1.557B Beat $1.470B Estimate
Incyte (NASDAQ:INCY) reported quarterly losses of $(3.60) per share which beat the analyst consensus estimate of $(3.85) by 6.49 percent. This is a 259.29 percent decrease over earnings of $2.26 per…
4 days ago businesswire.com
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates.
6 days ago seekingalpha.com
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript
1 week ago marketbeat.com
Incyte Highlights Promising Early Data for '890 and '734 in GI Cancers
Incyte NASDAQ: INCY presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “'890,”…
1 week ago zacks.com
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy
INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
1 week ago benzinga.com
Genmab's Encouraging Oncology Data Boosts Investor Optimism
Genmab shares positive petosemtamab trial data across multiple solid tumors at ESMO and partners with Incyte on targeted colorectal therapy.
1 week ago businesswire.com
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO26--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026.
1 week ago gurufocus.com
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
[url="]Genmab A/S[/url] (Nasdaq: GMAB) and [url="]Incyte[/url] (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's
1 week ago businesswire.com
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab's…
1 week ago gurufocus.com
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial collaboration to evaluate INCB161734, Incyte's investigational, potent and se
1 week ago businesswire.com
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)---- $INCY--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer.
1 week ago globenewswire.com
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Media ReleaseCOPENHAGEN, Denmark and WILMINGTON, Del. ; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated…
1 week ago zacks.com
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.
1 week ago marketbeat.com
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
Prelude Therapeutics NASDAQ: PRLD outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A…
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Incyte, Raises Price Target to $140
TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.
2 weeks ago benzinga.com
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
-
2 weeks ago benzinga.com
Truist Securities Maintains Hold on Incyte, Raises Price Target to $115
Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.
3 weeks ago benzinga.com
If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of…
-
4 weeks ago benzinga.com
Stifel Maintains Buy on Incyte, Raises Price Target to $157
Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.
1 month ago benzinga.com
If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of…
-
1 month ago benzinga.com
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.
-
1 month ago benzinga.com
JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123
JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.
1 month ago benzinga.com
FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss
FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.
1 month ago benzinga.com
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.
-
1 month ago benzinga.com
RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.
-
1 month ago benzinga.com
Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3
Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic…
1 month ago benzinga.com
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
1 month ago benzinga.com
Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’
CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.
1 month ago benzinga.com
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.